Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | MTOR | P42345 | 1/20 | 0.64 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.64 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.64 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.64 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | POLG | P54098 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11327207 | 1.00 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL11330336 | 0.98 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL3608348 | 0.92 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10177274 | 0.92 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL79966 | 0.92 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4735554 | 0.92 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL11617377 | 0.92 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18151989 | 0.92 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL2212574 | 0.92 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL11775328 | 0.90 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127822-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | PIERCE BIOTECHNOLOGY, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9828633-B1 | Modified nucleotides methods and kits | PIERCE BIOTECHNOLOGY, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9206216-B2 | Modified nucleotides methods and kits | PIERCE BIOTECHNOLOGY, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2669291-A1 | Modified Nucleotides Methods and Kits | Pierce Biotechnology, Inc. (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8536323-B2 | Modified nucleotides | PIERCE BIOTECHNOLOGY, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20120252691-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | PIERCE BIOTECHNOLOGY, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20110262917-A1 | MODIFIED NUCLEOTIDES | PIERCE BIOTECHNOLOGY, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-0777485-B1 | 2',5' PHOSPHOROTHIOATE/PHOSPHODIESTER OLIGOADENYLATES AND ANTIVIRAL USES THEREOF | UNIV TEMPLE (US) | 2003-02-19 | — | — | EP | disclosed |
| US-5863905-A | GREATLY ENHANCED METABOLIC STABILITY; NONHYDROLYZING; RESISTANCE TO SERUM PHOSPHODIESTERASES; NONTOXIC; INHIBIT OR ACTIVATE RIBONUCLEASE; AIDS, HTLV; HEPATITIS VIRUS; MS; PLANT VIRUSES, E.G. TOBACCO MOSAIC VIRUS; | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127822-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | RNGTT, NUDT1, ADAR | LMNA 195/4885THRB 1542/4885MTOR 4791/4885 |
| US-20120252691-A1 | MODIFIED NUCLEOTIDES METHODS AND KITS | RNGTT, NUDT1, ADAR | LMNA 195/4885THRB 1542/4885MTOR 4791/4885 |
| US-20110262917-A1 | MODIFIED NUCLEOTIDES | NUDT1, RNMT, RNGTT | LMNA 206/4885THRB 1275/4885MTOR 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.